China’s Research on COVID-19—Anti-Viral Antibodies
No.3  June 13, 2020

The COVID-19 pandemic is severely threatening human lives .Currently neutralizing antibodies are considered as potential therapeutic against the COVID-19. Since the outbreak of the pandemic, more than sixty institutes in China have engaged in research on viral antibodies and published 105 papers.

Yan Wu’s group isolated four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities. In particular B38 and H4 block the binding between virus S-protein RBD and cellular receptor ACE2. This was published in Science .

Chunyan Yi’s group demonstrated in Cellular & Molecular Immunology that the RBDs of SARS-CoV and SARS-CoV-2 are potential antigens that induce strong clade-specific neutralizing antibodies in mice, while the cross-neutralizing effect is much weaker, due to the differences in the antigenic features in the RBDs of the two viruses, which was carefully verified with the available neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.

Yunlong Cao’s group published in Cell that the 8558 distinct IgG1 clonotypes from 60 convalescent patients’ B cells were discovered, and further isolated fourteen potent neutralizing antibodies. The most potent antibody BD-368-2 exhibits high therapeutic and prophylactic efficacy in SARS-CoV-2-infected mice.

Rui Shi’s team isolated two specific human monoclonal antibodies from a convalescent COVID-19 patient reported in Nature. Antibodies CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro against SARS-CoV-2. In addition CB6 inhibited SARS-CoV-2 infection in rhesus monkeys at both prophylactic and treatment settings.

Bin Ju’s group reported in Nature that the isolation and characterization of two hundred and six RBD-specific monoclonal antibodies were derived from single B cells of eight SARS-CoV-2 infected individuals.
CopyRight © 中国国际科技交流中心 2020-All Right Reserverd 京ICP备05019987号-13